Evidence map›Paper›PMID 39042333›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

The first-in-human preclinical evaluation of the new probe [123I]I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT/CT imaging in prostate cancer.

Xiaohui Luan, Shaoxi Niu, Yachao Liu, Xiaojun Zhang, Xiaodan Xu, Shuwei Sun, Yabing Sun, Jingfeng Zhang, Yuan Wang, Zhiqiang Chen and 6 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [European journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaohui LuanDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Shaoxi NiuDepartment of Urology, The Third Medical Centre of Chinese PLA General Hospital, Beijing, China.
Yachao LiuDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Xiaojun ZhangDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Xiaodan XuDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Shuwei SunDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Yabing SunDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Jingfeng ZhangDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Yuan WangDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Zhiqiang ChenChinese PLA General Hospital, Chinese PLA Medical School, Beijing, China.
Yimin ChenKey Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
Mengchao CuiKey Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
Ruimin WangDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China.
Xu ZhangChinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. xzhang301@163.com.
Jinming ZhangDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China. zhangjm301@163.com.
Baixuan XuDepartment of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, China. xbx301@163.com.ORCID 0000-0002-6172-9896

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePSMA/PET has been increasingly used to detect PCa, and PSMA/PET-guided biopsy has shown promising results. However, it cannot be confirmed immediately whether the tissues are the targeted area. In this study, we aimed to develop a novel probe, [

methodsWe synthesized a high-affinity probe, [

resultsAnimal experiments verified the safety, targeting and effectiveness of [

conclusionWith the aid of [

trial registrationChinese Clinical trial registry ChiCTR2300069745, Registered 24 March 2023.

Indexed as

Image-Guided BiopsyProstatic NeoplasmsSingle Photon Emission Computed Tomography Computed TomographyAgedAnimalsHumansIntraoperative PeriodIodine RadioisotopesMaleMiceMiddle AgedOligopeptidesRadiopharmaceuticalsIodine-123Iodine RadioisotopesOligopeptidesRadiopharmaceuticals[123I]I-PSMA-7Clinical studyPSMA SPECT/CT imagingReal-time targeted biopsy

Identifiers

PMID39042333
PMCPMC11527917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.